| Fatakia, Adil |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 61 | Europe, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Recruiting | 2/3 | 560 | US | IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo | Incannex Healthcare Ltd | Obstructive Sleep Apnea | 12/26 | 12/26 | | |
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain |
|
|
| Active, not recruiting | 2/3 | 602 | US, RoW | Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly | Paradigm Biopharmaceuticals USA (INC) | Osteoarthritis, Knee | 10/24 | 01/25 | | |
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity |
|
|
| Recruiting | 2 | 360 | US, RoW | Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo | Eli Lilly and Company, Regeneron Pharmaceuticals | Obesity | 12/25 | 04/26 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
| Recruiting | 2 | 150 | US | CYR-064 | Cyrano Therapeutics, Inc. | Hyposmia | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
| Terminated | N/A | 800 | US | rapid in vitro diagnostic test, Sinu-Test®, bacterial culture, PCR assay | ENTvantage Dx, Beaufort | Sinusitis Bacterial | 04/23 | 04/23 | | |
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant |
|
|
| Recruiting | N/A | 50 | US | Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign | Spirair, Inc | Nasal Septal Deviation, Nasal Airway Obstruction | 12/24 | 07/25 | | |
NCT05591989: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects with Chronic Rhinitis (PARAGON) |
|
|
| Active, not recruiting | N/A | 80 | US | NEUROMARK System | Neurent Medical | Chronic Rhinitis | 06/25 | 06/25 | | |
| Chipman, Howard |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 610 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
